Off-label use is a very good thing, I think. In the case of one of the drugs we use to control pain, gabapentin, 90% is used off label. The label is for epilepsy, but in terms of controlling cancer pain, patients receiving gabapentin often need only about 10% of the amount of morphine and other drugs because they use it.
We should be collecting that information, though. This is why I think, for our proposal on new cancer drugs coming out, whether they're used on label or off label, I wouldn't want to interfere with that. But we should be collecting that data, and we're not. So we're not learning anything from it. Some of the uses of off label are actually a whole lot better than what they're labelled for.